• Bhubaneswar India
  • Contact+ 91-9938772605
  • Mon - Sat : 10:00AM - 6:00PM

Tag: Immunotherapy

CHAKRAVARTHI AVPS SEEN WITH Vice Minister for public health, , Thailand shri Thanakrit Jitareer
news

Unlocking Innovation: Chakravarthi AVPS Shares Industry Wisdom in Thailand

Jul 11, 2024 by Mansi 0 Comments #(FABA), #Academia-Industry Collaboration, #Alternative Proteins, #Antimicrobial Resistance, #Biotechnology, #Chakravarthi, #Chakravarthi AVPS, #Chief Operating Officer (FABA), #CPHI South East Asia 2024, #Crop Improvement, #Dr. Harinarayana Rao Research Director (Retired), #Dr. Jagadeesh Gandla, #drug-resistant infections, #EC member, #Gene Editing, #Immunotherapy, #industrial forum Global Framework for Biopharmaceuticals, #Infectious Diseases, #International Affairs the Federation of Asian Biotech Associations (FABA), #Jitareerat, #Recombinant Neutralising Antibodies for Emerging Infectious Diseases, #Regenerative Medicine, #Reliance Life Sciences, #Role of Academia and Industry interactions, #Role of Academia and Industry interactions in promoting Biotechnology and Trends, #Testing of Recombinant Neutralizing Antibodies of emergings, #Thailand at CPHI South East Asia, #Thailand's Vice minister for public health, #Thanakrit Jitareer

Hyderabad, July 11th, 2024 ….The city’s industry veteran Chakravarthi AVPS was invited to speak at an industrial forum Global Framework for Biopharmaceuticals, Thailand at CPHI South East Asia. CPHI South East Asia 2024 is a conference platform for people in the pharmaceutical industry in Southeast Asia.

He spoke on the Role of Academia and Industry interactions in promoting Biotechnology and Trends in Biotechnology: Testing of Recombinant Neutralising Antibodies for Emerging Infectious Diseases

Biotechnology is a Disruptive Force in Medicine, Agriculture & Industry he said, and spoke about a few trends in this sphere.

Precision Medicine (Tailoring treatments based on individual genetics); Gene Editing (Precise DNA modification for potential cures and disease prevention); Immunotherapy: (Harnessing the immune system to combat cancer); Regenerative Medicine (Repairing tissues and organs with stem cells and engineering); Crop Improvement: (Creating resilient, high-yield crops with less environmental impact.

Alternative Proteins: Developing sustainable plant-based and cultured meats) were the topics dealt with in the session

Speaking about Academia-Industry Collaboration, it is the need of the hour, he said and added that Partnerships accelerate research translation into real-world solutions. The gap is widening so much Chakravarthi added that combining academic knowledge with industry resources for efficient development is the need of the hour.

While speaking about the Talent Pipeline, training the next generation of biotechnologists through collaborative projects is the way forward, he observed.

The Urgent Need is Of course Tackling Infectious Diseases, he said.

Further, Mr Chakravarthi added that the Pandemic highlights the importance of rapid diagnostics and vaccine development.

He spoke about a big threat that looms large, that’s Antimicrobial Resistance. Biotechnology offers solutions to combat drug-resistant infections.

Vigilance and research are crucial to identifying and addressing new pathogens, he concluded his 30-minute note by addressing

Mr. Chakravarthi AVPS, Advisor & Board member, International Affairs the Federation of Asian Biotech Associations (FABA) was the lead speaker besides two other specialists from India— Dr. Jagadeesh Gandla, Chief Operating Officer (FABA) spoke on the Role of Academia and Industry interactions in promoting Biotechnology and Dr. Harinarayana Rao Research Director (Retired), Reliance Life Sciences. EC member, (FABA) who spoke on Testing of Recombinant Neutralizing Antibodies of emergings.

On the sidelines, Chakravarthi also interacted with Thailand’s Vice minister for public health, Thanakrit Jitareer at officiating the launch of the event. Mr Jitareerat was buoyant on global collaborations for enhancing healthcare reach to more people.

The meeting which began yesterday will go on next two days and will conclude on July 12th.

health

Management Strategies in Immunotherapy for Cancer Patients

Jul 5, 2024 by Sujata 0 Comments #Cancer Patients, #Dr. Kshitij Domadia, #Immunotherapy

Dr. Kshitij Domadia

 Dr. Kshitij Domadia, Consultant- Medical Oncology, HCG Cancer Centre, Ahmedabad.

Innovations in cancer treatment have ushered in a new era of hope and progress for patients worldwide. Among these advancements, Immunotherapy has emerged as a groundbreaking approach in cancer treatment, offering new hope for patients by harnessing the power of the immune system to combat cancer cells. While immunotherapy has revolutionized cancer care, it also presents unique challenges in management. From monitoring treatment response to managing immune-related adverse events (irAEs), healthcare providers must navigate a complex landscape to optimize patient outcomes.

 Understanding Immunotherapy
Unlike traditional cancer treatments such as chemotherapy and radiation therapy, which directly target cancer cells, immunotherapy works by enhancing the body’s immune response against cancer. This can involve stimulating the immune system to recognize and attack cancer cells more effectively or removing barriers that inhibit the immune response.

 Monitoring Treatment Response
Monitoring treatment response is crucial in immunotherapy to assess its effectiveness and guide treatment decisions. Healthcare providers use various methods, including imaging scans, blood tests, and clinical assessments, to evaluate tumor size, progression, and overall patient health. Regular monitoring allows for timely adjustments to treatment plans, such as switching to alternative therapies or combination approaches.

 Managing Immune-Related Adverse Events (irAEs)
While immunotherapy can be highly effective, it can also trigger immune-related adverse events (irAEs), which occur when the immune system attacks healthy tissues in addition to cancer cells. IrAEs can affect various organs and systems in the body, leading to symptoms ranging from mild to severe. Common irAEs include skin rash, colitis, pneumonitis, hepatitis, and endocrine disorders.

 Effective management of irAEs requires close collaboration between oncologists and multidisciplinary teams, including dermatologists, gastroenterologists, pulmonologists, and endocrinologists. Treatment may involve immunosuppressive medications, corticosteroids, or discontinuation of immunotherapy, depending on the severity and type of irAE. Early recognition and prompt intervention are essential to prevent irAEs from escalating and compromising patient safety.

 Personalized Approaches
Personalized medicine plays a vital role in optimizing immunotherapy management for cancer patients. Factors such as tumor type, genetic mutations, immune status, and patient comorbidities influence treatment decisions and response to immunotherapy. Biomarker testing, including PD-L1 expression and tumor mutational burden (TMB), helps identify patients who are most likely to benefit from immunotherapy and predict the risk of irAEs.

 Supportive Care
In addition to managing treatment-related side effects, supportive care is essential in immunotherapy to address the physical, emotional, and psychosocial needs of cancer patients. This includes symptom management, nutritional support, pain management, psychological counseling, and palliative care for patients with advanced or metastatic disease. Comprehensive supportive care enhances patient comfort, improves quality of life, and promotes treatment adherence.

 Looking Ahead
Immunotherapy represents a paradigm shift in cancer treatment, offering promising outcomes for many patients. However, effective management of immunotherapy requires a multifaceted approach that encompasses monitoring treatment response, managing irAEs, personalizing treatment strategies, and providing comprehensive supportive care. By navigating these challenges with expertise and compassion, healthcare providers can optimize the benefits of immunotherapy and improve outcomes for cancer patients.